TY - JOUR
T1 - Utility of a new bolus-injectable nanoparticle for clinical cancer staging
AU - Harisinghani, Mukesh
AU - Ross, Robert W.
AU - Guimaraes, Alexander R.
AU - Weissleder, Ralph
N1 - Funding Information:
Abbreviations: CNR, contrast-to-noise; MNP, magnetic nanoparticle; MRI, magnetic resonance imaging; SNR, signal-to-noise ratio Address all correspondence to: Mukesh Harisinghani, MD, Center for Molecular Imaging Research, Building 149, 13th Street, Room 5406, Charlestown, MA 02129-2060. E-mail: mharisinghani@partners.org 1This project was funded in part by federal funds from the National Cancer Institute, National Institutes of Health, under contract N01-CO-12400 (ClinicalTrials.gov Identifier: NCT00087347). Received 30 October 2007; Revised 30 October 2007; Accepted 31 October 2007.
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2007/12
Y1 - 2007/12
N2 - BACKGROUND: In this study, we report on the use of a new, bolus-injectable, carboxymethyl dextran-based magnetic nanoparticle (MNP), ferumoxytol, to improve detection in loco-regional lymph nodes by magnetic resonance imaging (MRI). METHODS: This preliminary study was performed as a prospective, single-center, open label pilot study to determine the magnitude of nodal MRI signal changes and to determine the optimal time points for imaging following intravenous (IV) bolus injection of the MNP. The study group consisted of 10 patients, all of whom were diagnosed with prostate cancer before any systemic therapy. RESULTS: All 10 patients had lymph nodes evaluated by histopathology. Of the evaluated 26 lymph nodes, 20 were benign and 6 were malignant. The mean short-axis diameter of benign lymph nodes was 6 mm and the mean short-axis diameter of malignant lymph nodes was 7 mm. Following IV administration, there was a significant change in mean signal-to-noise ratio (SNR) of benign lymph nodes (P < .0001) whereas there was little change in the mean SNR of malignant nodes (P = .1624). No adverse events were encountered. CONCLUSION: Ferumoxytol is safe and, at the appropriate circulation interval, modulates nodal signal intensity, allowing for identification of malignant nodal involvement by MRI.
AB - BACKGROUND: In this study, we report on the use of a new, bolus-injectable, carboxymethyl dextran-based magnetic nanoparticle (MNP), ferumoxytol, to improve detection in loco-regional lymph nodes by magnetic resonance imaging (MRI). METHODS: This preliminary study was performed as a prospective, single-center, open label pilot study to determine the magnitude of nodal MRI signal changes and to determine the optimal time points for imaging following intravenous (IV) bolus injection of the MNP. The study group consisted of 10 patients, all of whom were diagnosed with prostate cancer before any systemic therapy. RESULTS: All 10 patients had lymph nodes evaluated by histopathology. Of the evaluated 26 lymph nodes, 20 were benign and 6 were malignant. The mean short-axis diameter of benign lymph nodes was 6 mm and the mean short-axis diameter of malignant lymph nodes was 7 mm. Following IV administration, there was a significant change in mean signal-to-noise ratio (SNR) of benign lymph nodes (P < .0001) whereas there was little change in the mean SNR of malignant nodes (P = .1624). No adverse events were encountered. CONCLUSION: Ferumoxytol is safe and, at the appropriate circulation interval, modulates nodal signal intensity, allowing for identification of malignant nodal involvement by MRI.
KW - Ferumoxytol
KW - Lymph nodes
KW - MRI
KW - Nanoparticle
KW - Prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=37149030079&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=37149030079&partnerID=8YFLogxK
U2 - 10.1593/neo.07940
DO - 10.1593/neo.07940
M3 - Article
C2 - 18084623
AN - SCOPUS:37149030079
VL - 9
SP - 1160
EP - 1165
JO - Neoplasia (United States)
JF - Neoplasia (United States)
SN - 1522-8002
IS - 12
ER -